BGNE

BeiGene, Ltd.

150.86 USD
+0.06 (+0.04%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BeiGene, Ltd. stock is down -7.03% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 8 February’s closed higher than January. In the last 8 Unusual Options Trades, there were 3 CALLs, 5 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 Jan 14:40 17 May, 2024 190.00 CALL 45 17
09 Jan 15:17 16 Aug, 2024 200.00 PUT 9 0
10 Jan 16:58 19 Jan, 2024 175.00 PUT 59 15
10 Jan 19:07 19 Jan, 2024 175.00 PUT 60 15
24 Jan 14:49 17 May, 2024 190.00 CALL 50 152
29 Jan 20:36 16 Aug, 2024 280.00 PUT 50 4
01 Feb 19:31 17 May, 2024 190.00 CALL 150 176
09 Feb 20:46 16 Aug, 2024 200.00 PUT 10 10

About BeiGene, Ltd.

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma. Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC)